{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:18:00Z","timestamp":1776151080348,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:p><jats:italic>Abstract<\/jats:italic>\u2014We recently reported that norepinephrine and angiotensin II activate the Ras\/mitogen-activated protein (MAP) kinase pathway through generation of a cytochrome P450 (CYP450) and lipoxygenase metabolites. The purpose of this study was to determine the contribution of Ras\/MAP kinase to deoxycorticosterone acetate (DOCA)-salt\u2013induced hypertension in rats. Administration of DOCA and 1% saline drinking water to uninephrectomized rats for 6 weeks significantly elevated mean arterial blood pressure (MABP) (166\u00b15 mm Hg, n=19) compared with that of normotensive controls (95\u00b15 mm Hg, n=7) (<jats:italic>P<\/jats:italic>&lt;0.05). The activity of Ras and MAP kinase measured in the heart was increased in DOCA-salt hypertensive rats. Infusion of the Ras farnesyl transferase inhibitors FPT III (138 ng\/min) and BMS-191563 (694 ng\/min) significantly (<jats:italic>P<\/jats:italic>&lt;0.05) attenuated MABP to 139\u00b14 mm Hg (n=14) and 126\u00b11 mm Hg (n=4), respectively. Moreover, infusion of MAP kinase kinase inhibitor PD-98059 (694 ng\/min) also reduced MABP in hypertensive rats. Morphological studies of the kidney showed that treatment of rats with FPT III, which reduced Ras activity, minimized the hyperplastic occlusive arteriosclerosis and fibrinoid vasculitis observed in untreated hypertensive rats. In addition, the rise in CYP450 activity and MABP in hypertensive rats was prevented by the CYP450 inhibitor aminobenzotriazole (50 mg\/kg) and was associated with a decrease in Ras and MAP kinase activity in the heart. These data suggest that the Ras\/MAP kinase pathway contributes to DOCA-salt\u2013induced hypertension and associated vascular pathology consequent to activation of CYP450.<\/jats:p>","DOI":"10.1161\/01.hyp.35.1.457","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:25:31Z","timestamp":1339460731000},"page":"457-463","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Contribution of Ras GTPase\/MAP Kinase and Cytochrome P450 Metabolites to Deoxycorticosterone-Salt\u2013Induced Hypertension"],"prefix":"10.1161","volume":"35","author":[{"given":"Mubarack M.","family":"Muthalif","sequence":"first","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim F.","family":"Benter","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinat","family":"Khandekar","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Gaber","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Estes","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna","family":"Malik","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Hugues","family":"Parmentier","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeraswamy","family":"Manne","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kafait U.","family":"Malik","sequence":"additional","affiliation":[{"name":"From the Departments of Pharmacology (M.M.M., Z.K., A.E., S.M., J.-H.P., K.U.M.) and Pathology (L.G.), University of Tennessee, and the Southern College of Optometry, Division of Biomedical Sciences (I.F.B.), Memphis, Tenn; and the Department of Oncology Drug Discovery (V.M.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.47.30149"},{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(24)37208-8","volume":"284","year":"1998","unstructured":"Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin (1\u20137)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther.. 1998;284:388\u2013398.","journal-title":". J Pharmacol Exp Ther."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.79.2.271"},{"key":"e_1_3_2_4_2","first-page":"243","volume":"30","year":"1978","unstructured":"Moncada S, Vane JR. Pharmacology and endogenous role of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev. 1978;30:243\u2013331.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.31.040191.002011"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6301011"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.3.767"},{"key":"e_1_3_2_8_2","first-page":"I","volume":"23","year":"1994","unstructured":"Natarajan R, Gonzales N, Lanting L, Nadler J. Role of the lipoxygenase pathway in Ang II\u2013induced vascular smooth muscle cell hypertrophy. Hypertension. 1994;23:I-142\u2013I-147.","journal-title":"Hypertension"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/1050-1738(95)00106-9"},{"key":"e_1_3_2_10_2","first-page":"194","volume":"31","year":"1997","unstructured":"Nasjletti A. The role of eicosanoids in Ang II\u2013dependent hypertension. Hypertension. 1997;31:194\u2013200.","journal-title":"Hypertension"},{"key":"e_1_3_2_11_2","first-page":"A389","volume":"13","year":"1999","unstructured":"Alonso-Garcia A, Greene AS, Kurth TM, Cowley AW, Roman RJ. 20-HETE contributes to the renal vasoconstrictor actions of Ang II. FASEB J. 1999;13:A389. Abstract.","journal-title":"FASEB J"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.21.12701"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1996.271.4.C1212"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.31.1.242"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.31.5.1151"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.74.2.8293559"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1998.275.2.R426"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1999.276.3.R766"},{"key":"e_1_3_2_19_2","first-page":"A484","volume":"13","year":"1999","unstructured":"Benter I, Muthalif MM, Karzoun N, Fatima SF, Malik KU. Contribution of Ras GTPase to the development of Ang II-induced hypertension. FASEB J. 1999;13:A484. Abstract.","journal-title":"FASEB J"},{"key":"e_1_3_2_20_2","first-page":"88","volume":"49","year":"1943","unstructured":"Selge H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with DOCA and NaCl. Can Med Assoc J. 1943;49:88\u201392.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1976.56.1.1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1139\/y87-252"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198903000-00011"},{"key":"e_1_3_2_24_2","first-page":"469","volume":"17","year":"1985","unstructured":"Okada H, Suzuki H, Kanno Y, Saruta T. Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats. Clin Exp Hypertens. 1985;17:469\u2013483.","journal-title":"Clin Exp Hypertens"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.1.1.31"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13292.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16626.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.25.6.1191"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.4.6654"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702141"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.6.744"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0090-9556(25)07846-8","volume":"10","year":"1982","unstructured":"Orton TC, Parker GL. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat: induction of CYP-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metab Dispos. 1982;10:110\u2013115.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.32.19943"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.7.2901"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201005"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90307-C"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.13.5982"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.32.19925"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.37.1.143"},{"key":"e_1_3_2_40_2","first-page":"19","volume":"36","year":"1943","unstructured":"Selge H, Hall CE. Pathologic changes induced in various species by overdosage with DOCA. Arch Pathol. 1943;36:19\u201331.","journal-title":"Arch Pathol"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.51.3.7116579"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.53.4.6627608"},{"key":"e_1_3_2_43_2","first-page":"2","volume":"32","year":"1973","unstructured":"Folkow B, Hallback M, Lundren Y, Sivertsson R, Weiss L. Importance of adaptive change in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res. 1973;32:2\u201316.","journal-title":"Circ Res"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.35.1.457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:45:19Z","timestamp":1743363919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.35.1.457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1161\/01.HYP.35.1.457"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.35.1.457","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]},"assertion":[{"value":"1999-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}